|
|
 |
|
Viewing report
|
|
|
|
Injectable Generic Drugs: Prospects & Opportunities to 2013
Espicom Business Intelligence Ltd, July 2008, Pages: 264
This report provides:
- Individual analysis of 48 leading therapies
- Product forecasts by value 2008/2013
- Comprehensive patent information by product and patent expiry opportunities to 2015
- The market context for injectable drugs
- Evaluation of companies competing in the sector
- Analysis of significant litigation
Key therapy sectors covered:
- Cancer
- CNS
- Cardiovascular
- Anti-Infectives
- Diabetes
- Growth Disorders
Some of the most promising generic drug opportunities due to come off patent in the USA and Europe over the next few years are injectable:
This new report focuses on the market potential for sterile drugs delivered by injection or infusion. These drugs are used to treat major illnesses, such as cancer, central nervous system (CNS) disorders, acute cardiovascular conditions and severe infections. More than one third of the injectable generics approved in the US during the last five years are used in cancer therapy. A further 23% are anti-infectives, 16% are used in the CNS setting and 9% are used for cardiovascular therapy.
A relatively small number of injectable drugs have received significant attention from generic companies, resulting in the approval of numerous versions following patent expiry. Some of these are high profile cancer drugs. For example, when Bristol-Myers Squibb’s Paraplatin (carboplatin) became generically available 11 companies received FDA approval for generic versions.
Significant opportunities still exist:
Obviously where intense competition exists, the potential for significant market share is reduced. The vast majority of injectable generics are, however, less hotly contested. For more than half of the injectable generics approved since 2003, just one or two manufacturers have received ANDA approvals and over 85% of molecules have less than five generic competitors. While the potential market may not be as valuable for these products, with less competition for price reductions, higher profit margins than have traditionally been available for oral generics are possible. Companies are, therefore, able to capitalise on opportunities for specialty injectable generics in niche areas.
Customers who bought this item also bought
Injectable Generic Drugs: Prospects and Opportunities to 2010
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Emerging Opportunities in Controlled-Release Generic Drugs
U.S. Generic Pharmaceuticals Outlook
GenericHandbook - A Guide to the Generic Drug Industry in the US
Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition
The World Generic Market Report 2008
Booming US Generic Drug Market
Generic Drug Market in Canada
Generic Pharmaceuticals Business Intelligence Report
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
|
|
|
|
